Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 7/20 | 0.38 |
| ▸ | BRD2 | P25440 | 2/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 4/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.34 |
| ▸ | EP300 | Q09472 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20547070 | 0.93 | CYP3A4 (0.41) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL20547087 | 0.89 | CYP3A4 (0.42) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL18359596 | 0.87 | CYP3A4 (0.41) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL18359666 | 0.83 | CYP3A4 (0.48) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL18359598 | 0.82 | CYP3A4 (0.41) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL18359639 | 0.79 | CYP3A4 (0.44) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL18359573 | 0.79 | CYP3A4 (0.41) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL18359571 | 0.77 | CYP3A4 (0.43) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL18359594 | 0.73 | OPRM1 (0.38) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL18359549 | 0.73 | BRD4 (0.49) | CYP3A4CYP2C9BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORP (FI) | 2018-11-01 | — | — | US | disclosed |
| WO-2017001733-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312496-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD4, BRD2 | CYP3A4 2191/4885CYP2C9 2110/4885BRD4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.